Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Ginkgo has signed multiple collaborations, announced a breakthrough in manufacturing mRNA vaccine components, and landed an SPAC deal.
Junshi Biosciences announced that the Phase III clinical trial it is conducting alongside Coherus BioSciences on a potential non-small cell lung cancer drug shows positive preliminary results.
August has been busy with a flurry of life sciences expansion announcements, particularly in the United States and Canada. Here’s a look at a few companies increasing their presence in the two countries.
Global biopharma and life sciences companies provide updates to their businesses and pipelines.
Here’s the shortlist of which life sciences companies took a dip in the money pool this week.
The companies will use their funds to support the development of their lead assets and advance their pipelines.
The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
Two months after Athira placed its CEO Leen Kawas, on temporary leave, the company has appointed new execs to its team. It is also rigorously advancing its Alzheimer’s program.
CureVac has revealed in its latest financial report that its lung cancer program with German biotechnology company Boehringer Ingelheim has been terminated.
Eli Lilly is undertaking a strategic transformation that will result in the formation of new business units.